Encapsulated cell biodelivery of GDNF: A novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Wahlberg Lars) > Encapsulated cell b...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		02816naa a2200301 4500
001		oai:lup.lub.lu.se:1a6d4437-36cd-4f96-be4a-bca512d52e85
003		SwePub
008		160401s2008 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a https://lup.lub.lu.se/record/6082832 URI
024	7	a https://doi.org/10.1016/j.expneurol.2007.08.0192 DOI
040		a (SwePub)lu
041		a engb eng
042		9 SwePub
072	7	a art2 swepub-publicationtype
072	7	a ref2 swepub-contenttype
100	1	a Lindvall, Olleu Lund University,Lunds universitet,Wallenberg Neurocentrum, Lund,Medicinska fakulteten,Wallenberg Neuroscience Centre, Lund,Faculty of Medicine4 aut0 (Swepub:lu)neur-oli
245	1 0	a Encapsulated cell biodelivery of GDNF: A novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?
264	1	b Elsevier BV,c 2008
520		a The main pathology underlying disease symptoms in Parkinson's disease (PD) is a progressive degeneration of nigrostriatal dopamine (DA) neurons. No effective disease-modifying treatment currently exists. Glial cell line-derived neurotrophic factor (GDNF) has neuroprotective and neuroregenerative effects and it enhances dopaminergic function in animal models of PD. These findings raise the possibility that intrastriatal administration of GDNF might be developed into a new clinical strategy for functional preservation and restoration also in PD patients. Gene therapy is a novel toot to increase local levels of GDNF. Transplantation of encapsulated, GDNF-secreting cells is one strategy for ex vivo cell-based gene delivery which has the advantage to allow for removal of the cells if untoward effects occur. Here we summarize studies with such cells in animals, and discuss the results from previous trials with GDNF in PD patients and their implications for the further development of neuroprotective/neuroregenerative therapies. Finally, we describe the different scientific and regulatory issues that need to be addressed in order to reach the clinic and start the first trial in patients. (c) 2007 Elsevier Inc. All rights reserved.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng
700	1	a Wahlberg, Lars U4 aut
710	2	a Wallenberg Neurocentrum, Lundb Medicinska fakulteten4 org
773	0	t Experimental Neurologyd : Elsevier BVg 209:1, s. 82-88q 209:1<82-88x 0014-4886
856	4	u http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17963752&dopt=Abstracty FULLTEXT
856	4	u http://dx.doi.org/10.1016/j.expneurol.2007.08.019y FULLTEXT
856	4 8	u https://lup.lub.lu.se/record/608283
856	4 8	u https://doi.org/10.1016/j.expneurol.2007.08.019

Hitta via bibliotek

Experimental Neurology (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Lindvall, Olle; Wahlberg, Lars U

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Neurologi

Artiklar i publikationen: Experimental Neu ...

Av lärosätet: Lunds universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se